Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Journal of Magnetic Resonance Imaging : JMRI
|
May 20, 1999
Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA)
R Manfredi, G Maresca, R L Baron, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
August 14, 1998
Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis
R Manfredi, G Maresca, R L Baron, et al.
American Journal of Medical Genetics. Part A
|
April 5, 2023
Adverse childhood experiences and the development of Down syndrome regression disorder
Sarah Wang, Lina Patel, Elise A Sannar, et al.
Journal of Neurodevelopmental Disorders
|
October 25, 2023
Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder
Natalie K Boyd, Julia Nguyen, Mellad M Khoshnood, et al.
AJR. American Journal of Roentgenology
|
September 23, 2000
Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions
G Pirovano, A Vanzulli, L Marti-Bonmati, et al.
Korean Journal of Radiology
|
January 5, 2002
Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial
C S Peña, S Saini, R L Baron, et al.
The British Journal of Radiology
|
January 20, 2006
Diagnostic efficacy of SonoVue, a second generation contrast agent, in the assessment of extracranial carotid or peripheral arteries using colour and spectral Doppler ultrasound: a multicentre study
P S Sidhu, P L Allan, F Cattin, et al.
Molecular Autism
|
January 29, 2026
Serum and cerebral folate are normal in down syndrome regression disorder
Jonathan D Santoro, Mackenzie Silverman, Lilia Kazerooni, et al.
Scientific Reports
|
December 28, 2024
Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder
Jonathan D Santoro, Saba Jafarpour, Laura Keehan, et al.
Neurology and Therapy
|
March 8, 2026
A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder
Jonathan D Santoro, Saba Jafarpour, Panteha Hayati Rezvan, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Journal of Magnetic Resonance Imaging : JMRI
|
May 20, 1999
Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA)
R Manfredi, G Maresca, R L Baron, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
August 14, 1998
Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis
R Manfredi, G Maresca, R L Baron, et al.
American Journal of Medical Genetics. Part A
|
April 5, 2023
Adverse childhood experiences and the development of Down syndrome regression disorder
Sarah Wang, Lina Patel, Elise A Sannar, et al.
Journal of Neurodevelopmental Disorders
|
October 25, 2023
Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder
Natalie K Boyd, Julia Nguyen, Mellad M Khoshnood, et al.
AJR. American Journal of Roentgenology
|
September 23, 2000
Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions
G Pirovano, A Vanzulli, L Marti-Bonmati, et al.
Korean Journal of Radiology
|
January 5, 2002
Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial
C S Peña, S Saini, R L Baron, et al.
The British Journal of Radiology
|
January 20, 2006
Diagnostic efficacy of SonoVue, a second generation contrast agent, in the assessment of extracranial carotid or peripheral arteries using colour and spectral Doppler ultrasound: a multicentre study
P S Sidhu, P L Allan, F Cattin, et al.
Molecular Autism
|
January 29, 2026
Serum and cerebral folate are normal in down syndrome regression disorder
Jonathan D Santoro, Mackenzie Silverman, Lilia Kazerooni, et al.
Scientific Reports
|
December 28, 2024
Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder
Jonathan D Santoro, Saba Jafarpour, Laura Keehan, et al.
Neurology and Therapy
|
March 8, 2026
A Comparative Effectiveness Study of Lorazepam or IVIg Versus no Treatment for Down Syndrome Regression Disorder
Jonathan D Santoro, Saba Jafarpour, Panteha Hayati Rezvan, et al.
Page
of 5